# A Study of DOXIL/CAELYX in Patients With Advanced or Refractory Solid Malignancies Including Patients With Ovarian Cancer

> **NCT02081495** · PHASE1 · COMPLETED · sponsor: **Janssen Research & Development, LLC** · enrollment: 35 (actual)

## Conditions studied

- Neoplasms

## Interventions

- **DRUG:** DOXIL/CAELYX reference product (Treatment A)
- **DRUG:** DOXIL/CAELYX test product (Treatment B)

## Key facts

- **NCT ID:** NCT02081495
- **Lead sponsor:** Janssen Research & Development, LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-08
- **Primary completion:** 2015-11
- **Final completion:** 2015-11
- **Target enrollment:** 35 (ACTUAL)
- **Last updated:** 2016-11-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02081495

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02081495, "A Study of DOXIL/CAELYX in Patients With Advanced or Refractory Solid Malignancies Including Patients With Ovarian Cancer". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02081495. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*